Quantitative MRI reveals aging‐associated T2 changes in mouse models of Alzheimer's disease

In this study, we used MRI to analyze quantitative parametric maps of transverse (T2) relaxation times in a longitudinal study of transgenic mice expressing mutant forms of amyloid precursor protein (APP), presenilin (PS1), or both (PS/APP), modeling aspects of Alzheimer's disease (AD). The main goal was to characterize the effects of progressive β‐amyloid accumulation and deposition on the biophysical environment of water and to investigate if these measurements would provide early indirect evidence of AD pathological changes in the brains of these mice. Our results demonstrate that at an early age before β‐amyloid deposition, only PS/APP mice show a reduced T2 in the hippocampus and cortex compared with wild‐type non‐transgenic (NTg) controls, whereas a statistically significant within‐group aging‐associated decrease in T2 values is seen in the cortex and hippocampus of all three transgenic genotypes (APP, PS/APP, and PS) but not in the NTg controls. In addition, for animals older than 12 months, we confirmed our previous report that only the two genotypes that form amyloid plaques (APP and PS/APP) have significantly reduced T2 values compared with NTg controls. Thus, T2 changes in these AD models can precede amyloid deposition or even occur in AD models that do not deposit β‐amyloid (PS mice), but are intensified in the presence of amyloid deposition. Copyright © 2007 John Wiley & Sons, Ltd.

[1]  J. McCarthy,et al.  Involvement of presenilins in cell-survival signalling pathways. , 2005, Biochemical Society transactions.

[2]  D. Dickson,et al.  Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes , 1999, Neurobiology of Disease.

[3]  M. Bunsey,et al.  Differential Effects of Dorsal and Ventral Hippocampal Lesions , 1998, The Journal of Neuroscience.

[4]  Thomas Wisniewski,et al.  Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging , 2003, Magnetic resonance in medicine.

[5]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[6]  A Van der Linden,et al.  Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease , 2005, Magnetic resonance in medicine.

[7]  R. Kauppinen,et al.  Graded Reduction of Cerebral Blood Flow in Rat as Detected by the Nuclear Magnetic Resonance Relaxation Time T2: A Theoretical and Experimental Approach , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  Thomas Wisniewski,et al.  Amyloid‐β Deposition Is Associated with Decreased Hippocampal Glucose Metabolism and Spatial Memory Impairment in APP/PS1 Mice , 2004 .

[9]  D J Jenden,et al.  In vivo proton magnetic resonance spectroscopy of the normal aging human brain. , 1996, Life sciences.

[10]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[11]  T. Groen,et al.  Transgenic mice expressing the human presenilin 1 gene demonstrate enhanced hippocampal reorganization following entorhinal cortex lesions , 2002, Brain Research Bulletin.

[12]  Thomas Wisniewski,et al.  Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging , 2002, Neurobiology of Disease.

[13]  Jaime Grutzendler,et al.  Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches , 2004, Nature Neuroscience.

[14]  Thomas Wisniewski,et al.  Magnetic Resonance in Medicine 51:794–798 (2004) MRI Assessment of Neuropathology in a Transgenic Mouse Model of Alzheimer’s Disease , 2022 .

[15]  B. Hyman,et al.  Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. , 2000, The American journal of pathology.

[16]  Joseph A. Helpern,et al.  Histological Co-Localization of Iron in Aß Plaques of PS/APP Transgenic Mice , 2005, Neurochemical Research.

[17]  M. F. Falangola,et al.  Visualization of β‐amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents , 2004, Magnetic resonance in medicine.

[18]  D. Treit,et al.  Dorsal and ventral hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests , 2002, Brain Research.

[19]  Marc Dhenain,et al.  Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease , 2006, Neurobiology of Disease.

[20]  D. Davies,et al.  Neurodegenerative Changes Associated with β-Amyloid Deposition in the Brains of Mice Carrying Mutant Amyloid Precursor Protein and Mutant Presenilin-1 Transgenes , 2001, Experimental Neurology.

[21]  E. Kandel,et al.  Loss of Presenilin Function Causes Impairments of Memory and Synaptic Plasticity Followed by Age-Dependent Neurodegeneration , 2004, Neuron.

[22]  Clifford R Jack,et al.  In Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice , 2005, The Journal of Neuroscience.

[23]  Susumu Mori,et al.  Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging , 2004, Magnetic resonance in medicine.

[24]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[25]  K. Duff,et al.  Reorganization of Cholinergic Terminals in the Cerebral Cortex and Hippocampus in Transgenic Mice Carrying Mutated Presenilin-1 and Amyloid Precursor Protein Transgenes , 1999, The Journal of Neuroscience.

[26]  Michael Garwood,et al.  In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent , 2004, Magnetic resonance in medicine.

[27]  R. Kesner,et al.  Patterns of hippocampal cell loss based on subregional lesions of the hippocampus , 2005, Brain Research.

[28]  G. Higgins,et al.  Transgenic mouse models of Alzheimer's disease: phenotype and application , 2003, Behavioural pharmacology.

[29]  R. Empson,et al.  Functional Phenotype in Transgenic Mice Expressing Mutant Human Presenilin-1 , 2000, Neurobiology of Disease.

[30]  C. Lemere,et al.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. , 2001, The American journal of pathology.

[31]  K. Duff,et al.  Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain , 2000, Neuroscience.

[32]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.